Fraud, Lies, Exploitation and Eugenic Fantasies
By Emile P. Torres,
Truthdig
| 11. 09. 2023
It’s been a no good, very bad year for Effective Altruism, or “EA” for short, the cultural movement that aims to use “evidence and reason” to figure out the best ways to do the “most good.”
One year ago, the EA community was flying high. Its poster boy, a philosopher named William MacAskill, had just published his book “What We Owe the Future,” which makes the case that we should be far more concerned about humanity’s long-term future — thousands, millions, even billions of years from now — than we ordinarily are. Effective Altruists call this “longtermism,” an idea built around a vision of the future in which we reengineer humanity, colonize space, plunder the vast resources of the cosmos, and ultimately maximize the total amount of “value” in the universe by creating huge numbers of “digital people” living “happy” lives in giant computer simulations.
If this sounds bizarre and potentially dangerous, that’s because it is. Yet MacAskill’s book, longtermism and the EA movement that he co-founded received mostly favorable coverage from...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick, Issues in Science and Technology | 07.04.2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...